α₁-Antitrypsin Deficiency in Childhood

 

 Buy Article Permissions and Reprints

ABSTRACT

α₁-Antitrypsin deficiency is a common genetic disease in which individuals homozygous for the mutant Z allele are at risk for the development of liver disease and emphysema. The mutant Z protein product is synthesized in hepatocytes but then accumulates intracellularly rather then being appropriately secreted. The effects of the intracellular accumulation of the mutant Z protein in the liver include the formation of protein polymers, activation of autophagy, mitochondrial injury, and caspase activation, which progress in a cascade causing hepatocellular injury. Liver disease can occur at any age, although the majority of children are free of significant liver dysfunction. The variable clinical presentations suggest an important contribution of genetic and environmental disease modifiers. The heterozygous carrier state for the mutant Z gene, present in 1.5% to 3% of the population, is not itself a common cause of liver injury but may be a modifier gene for other liver diseases.

REFERENCES

• 1 Teckman J H, Lindblad D. Alpha-1-antitrypsin deficiency: diagnosis, pathophysiology, and management.  Curr Gastroenterol Rep. 2006;  8 14-20
  CrossrefPubMedGoogle Scholar
• 2 Rudnick D A, Liao Y, An J K, Muglia L J, Perlmutter D H, Teckman J H. Analyses of hepatocellular proliferation in a mouse model of alpha-1-antitrypsin deficiency.  Hepatology. 2004;  39 1048-1055
  CrossrefPubMedGoogle Scholar
• 3 American Thoracic Society/European Respiratory Society Statement . Standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency.  Am J Respir Crit Care Med. 2003;  168 818-900
  CrossrefPubMedGoogle Scholar
• 4 Qu D, Teckman J H, Perlmutter D H. Review: alpha 1-antitrypsin deficiency associated liver disease.  J Gastroenterol Hepatol. 1997;  12 404-416
  PubMedGoogle Scholar
• 5 Eriksson S. Discovery of alpha 1-antitrypsin deficiency.  Lung. 1990;  168(suppl) 523-529
  PubMedGoogle Scholar
• 6 Eriksson S. Alpha 1-antitrypsin deficiency.  J Hepatol. 1999;  30(suppl 1) 34-39
  PubMedGoogle Scholar
• 7 Eriksson S. A 30-year perspective on alpha 1-antitrypsin deficiency.  Chest. 1996;  110(suppl) 237S-242S
  PubMedGoogle Scholar
• 8 Perlmutter D H. Alpha-1-antitrypsin deficiency: diagnosis and treatment.  Clin Liver Dis. 2004;  8 839-859
  CrossrefPubMedGoogle Scholar
• 9 Sveger T. Liver disease in alpha1-antitrypsin deficiency detected by screening of 200,000 infants.  N Engl J Med. 1976;  294 1316-1321
  CrossrefPubMedGoogle Scholar
• 10 Sveger T. Alpha 1-antitrypsin deficiency in early childhood.  Pediatrics. 1978;  62 22-25
  PubMedGoogle Scholar
• 11 An J K, Blomenkamp K, Lindblad D, Teckman J H. Quantitative isolation of alphalAT mutant Z protein polymers from human and mouse livers and the effect of heat.  Hepatology. 2005;  41 160-167
  CrossrefPubMedGoogle Scholar
• 12 Sveger T, Eriksson S. The liver in adolescents with alpha 1-antitrypsin deficiency.  Hepatology. 1995;  22 514-517
  PubMedGoogle Scholar
• 13 Sveger T. The natural history of liver disease in alpha 1-antitrypsin deficient children.  Acta Paediatr Scand. 1988;  77 847-851
  PubMedGoogle Scholar
• 14 Mowat A P. Alpha 1-antitrypsin deficiency (PiZZ): features of liver involvement in childhood.  Acta Paediatr Suppl. 1994;  393 13-17
  PubMedGoogle Scholar
• 15 Pittschieler K, Massi G. Alpha 1 antitrypsin deficiency in two population groups in north Italy.  Padiatr Padol. 1988;  23 307-311
  PubMedGoogle Scholar
• 16 Eriksson S. Alpha-1-antitrypsin deficiency: natural course and therapeutic strategies. In: Boyer JL, Blum HE, Maier K-P, Sauerbruch T, Stalder GA Falk Symposium 115: Liver Cirrhosis and Its Development. Dordrecht; Kluwer Academic Publishers 2001: 307-315
  Google Scholar
• 17 Sveger T, Piitulainen E, Arborelius Jr M. Lung function in adolescents with alpha 1-antitrypsin deficiency.  Acta Paediatr. 1994;  83 1170-1173
  PubMedGoogle Scholar
• 18 Eden E, Hammel J, Rouhani F N et al.. Asthma features in severe alpha1-antitrypsin deficiency: experience of the National Heart, Lung, and Blood Institute Registry.  Chest. 2003;  123 765-771
  CrossrefPubMedGoogle Scholar
• 19 Lomas D A, Finch J T, Seyama K, Nukiwa T, Carrell R W. Alpha 1-antitrypsin Siiyama (Ser53→Phe): further evidence for intracellular loop-sheet polymerization.  J Biol Chem. 1993;  268 15333-15335
  PubMedGoogle Scholar
• 20 Lomas D A, Elliott P R, Sidhar S K et al.. Alpha 1-antitrypsin Mmalton (Phe52-deleted) forms loop-sheet polymers in vivo: evidence for the C sheet mechanism of polymerization.  J Biol Chem. 1995;  270 16864-16870
  CrossrefPubMedGoogle Scholar
• 21 Laurell C B, Sveger T. Mass screening of newborn Swedish infants for alpha antitrypsin deficiency.  Am J Hum Genet. 1975;  27 213-217
  PubMedGoogle Scholar
• 22 Sveger T, Thelin T, McNeil T F. Young adults with alpha 1-antitrypsin deficiency identified neonatally: their health, knowledge about and adaptation to the high-risk condition.  Acta Paediatr. 1997;  86 37-40
  PubMedGoogle Scholar
• 23 McNeil T F, Sveger T, Thelin T. Psychosocial effects of screening for somatic risk: the Swedish alpha 1 antitrypsin experience.  Thorax. 1988;  43 505-507
  PubMedGoogle Scholar
• 24 Piitulainen E, Sveger T. Respiratory symptoms and lung function in young adults with severe alpha(1)-antitrypsin deficiency (PiZZ).  Thorax. 2002;  57 705-708
  CrossrefPubMedGoogle Scholar
• 25 Teckman J H. Lack of effect of oral 4-phenylbutyrate on serum alpha-1-antitrypsin in patients with alpha-1-antitrypsin deficiency: a preliminary study.  J Pediatr Gastroenterol Nutr. 2004;  39 34-37
  PubMedGoogle Scholar
• 26 Duan Y Y, Wu J, Zhu J L et al.. Gene therapy for human alpha1-antitrypsin deficiency in an animal model using SV40-derived vectors.  Gastroenterology. 2004;  127 1222-1232
  CrossrefPubMedGoogle Scholar
• 27 Lomas D A, Mahadeva R. Alpha1-antitrypsin polymerization and the serpinopathies: pathobiology and prospects for therapy.  J Clin Invest. 2002;  110 1585-1590
  CrossrefPubMedGoogle Scholar
• 28 Wu Y, Whitman I, Molmenti E, Moore K, Hippenmeyer P, Perlmutter D H. A lag in intracellular degradation of mutant alpha 1-antitrypsin correlates with the liver disease phenotype in homozygous PiZZ alpha 1-antitrypsin deficiency.  Proc Natl Acad Sci USA. 1994;  91 9014-9018
  CrossrefPubMedGoogle Scholar
• 29 Qu D, Teckman J H, Omura S, Perlmutter D H. Degradation of a mutant secretory protein, alpha1-antitrypsin Z, in the endoplasmic reticulum requires proteasome activity.  J Biol Chem. 1996;  271 22791-22795
  CrossrefPubMedGoogle Scholar
• 30 Dafforn T R, Mahadeva R, Elliott P R, Sivasothy P, Lomas D A. A kinetic mechanism for the polymerization of alpha1-antitrypsin.  J Biol Chem. 1999;  274 9548-9555
  CrossrefPubMedGoogle Scholar
• 31 Lomas D A, Evans D L, Finch J T, Carrell R W. The mechanism of Z alpha 1-antitrypsin accumulation in the liver.  Nature. 1992;  357 605-607
  CrossrefPubMedGoogle Scholar
• 32 Cabral C M, Choudhury P, Liu Y, Sifers R N. Processing by endoplasmic reticulum mannosidases partitions a secretion-impaired glycoprotein into distinct disposal pathways.  J Biol Chem. 2000;  275 25015-25022
  CrossrefPubMedGoogle Scholar
• 33 Teckman J H, Burrows J, Hidvegi T, Schmidt B, Hale P D, Perlmutter D H. The proteasome participates in degradation of mutant alpha 1-antitrypsin Z in the endoplasmic reticulum of hepatoma-derived hepatocytes.  J Biol Chem. 2001;  276 44865-44872
  CrossrefPubMedGoogle Scholar
• 34 Teckman J H, Perlmutter D H. Retention of mutant alpha(1)-antitrypsin Z in endoplasmic reticulum is associated with an autophagic response.  Am J Physiol Gastrointest Liver Physiol. 2000;  279 G961-G974
  PubMedGoogle Scholar
• 35 Sifers R N. Cell biology: protein degradation unlocked.  Science. 2003;  299 1330-1331
  CrossrefPubMedGoogle Scholar
• 36 Lomas D A, Parfrey H. Alpha1-antitrypsin deficiency. 4: molecular pathophysiology.  Thorax. 2004;  59 529-535
  CrossrefPubMedGoogle Scholar
• 37 Perlmutter D H. Alpha1-antitrypsin deficiency: liver disease associated with retention of a mutant secretory glycoprotein in the endoplasmic reticulum.  Methods Mol Biol. 2003;  232 39-56
  PubMedGoogle Scholar
• 38 Lomas D A, Evans D L, Stone S R, Chang W S, Carrell R W. Effect of the Z mutation on the physical and inhibitory properties of alpha 1-antitrypsin.  Biochemistry. 1993;  32 500-508
  CrossrefPubMedGoogle Scholar
• 39 Lin L, Schmidt B, Teckman J, Perlmutter D H. A naturally occurring nonpolymerogenic mutant of alpha 1-antitrypsin characterized by prolonged retention in the endoplasmic reticulum.  J Biol Chem. 2001;  276 33893-33898
  CrossrefPubMedGoogle Scholar
• 40 Wu Y, Swulius M T, Moremen K W, Sifers R N. Elucidation of the molecular logic by which misfolded alpha 1-antitrypsin is preferentially selected for degradation.  Proc Natl Acad Sci USA. 2003;  100 8229-8234
  CrossrefPubMedGoogle Scholar
• 41 Lawless M W, Greene C M, Mulgrew A, Taggart C C, O'Neill S J, McElvaney N G. Activation of endoplasmic reticulum-specific stress responses associated with the conformational disease Z alpha 1-antitrypsin deficiency.  J Immunol. 2004;  172 5722-5726
  PubMedGoogle Scholar
• 42 Teckman J H, An J K, Blomenkamp K, Schmidt B, Perlmutter D. Mitochondrial autophagy and injury in the liver in alpha 1-antitrypsin deficiency.  Am J Physiol Gastrointest Liver Physiol. 2004;  286 G851-G862
  CrossrefPubMedGoogle Scholar
• 43 Teckman J H, An J K, Loethen S, Perlmutter D H. Fasting in alpha1-antitrypsin deficient liver: constitutive [correction of consultative] activation of autophagy.  Am J Physiol Gastrointest Liver Physiol. 2002;  283 G1156-G1165
  PubMedGoogle Scholar
• 44 Teckman J H, Perlmutter D H. The endoplasmic reticulum degradation pathway for mutant secretory proteins alpha1-antitrypsin Z and S is distinct from that for an unassembled membrane protein.  J Biol Chem. 1996;  271 13215-13220
  CrossrefPubMedGoogle Scholar
• 45 Marcus N Y, Perlmutter D H. Glucosidase and mannosidase inhibitors mediate increased secretion of mutant alpha1 antitrypsin Z.  J Biol Chem. 2000;  275 1987-1992
  CrossrefPubMedGoogle Scholar
• 46 Rudnick D A, Shikapwashya O, Blomenkamp K, Teckman J H. Indomethacin increases liver damage in a murine model of liver injury from alpha-1-antitrypsin deficiency.  Hepatology. 2006;  44 976-982
  CrossrefPubMedGoogle Scholar
• 47 Pittschieler K. Liver disease and heterozygous alpha-1-antitrypsin deficiency.  Acta Paediatr Scand. 1991;  80 323-327
  PubMedGoogle Scholar
• 48 Kaserbacher R, Propst T, Propst A, Graziadei I, Judmaier G, Vogel W. Association between heterozygous alpha 1-antitrypsin deficiency and genetic hemochromatosis.  Hepatology. 1993;  18 707-708
  PubMedGoogle Scholar
• 49 Propst T, Propst A, Dietze O, Judmaier G, Braunsteiner H, Vogel W. High prevalence of viral infection in adults with homozygous and heterozygous alpha 1-antitrypsin deficiency and chronic liver disease.  Ann Intern Med. 1992;  117 641-645
  CrossrefPubMedGoogle Scholar
• 50 Mahadeva R, Chang W S, Dafforn T R et al.. Heteropolymerization of S, I, and Z alpha1-antitrypsin and liver cirrhosis.  J Clin Invest. 1999;  103 999-1006
  PubMedGoogle Scholar

Jeffrey H TeckmanM.D. 

Department of Pediatrics, St. Louis University, Cardinal Glennon Children's Medical Center

1465 South Grand Blvd., St. Louis, MO 63104